Phaseline

Companies › Neurocrine Switzerland

Neurocrine Switzerland: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Genitourinary; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Crinecerfont
Corticotropin releasing factor receptor 1 antagonist
CRHR1Phase 2Congenital Adrenal HyperplasiaMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07536269CrinecerfontPhase 2Congenital Adrenal HyperplasiaGenitourinaryMar 2028
NCT07187375CrinecerfontPhase 2Congenital Adrenal HyperplasiaGenitourinarySep 2029

From the company's SEC filings

Cash and short-term investments of $738m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CRHR1 (1)

Companies with the same targets

Chiesi Farmaceutici Shionogi Neurocrine Biosciences

Companies built like this

Kira Pharmacenticals (US) Veloxis Pharmaceuticals Juro Sciences Vifor Fresenius Medical Care Renal Pharma Vaneltix Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.